Which Hypoglycaemic Agents to use in Type 2 Diabetes and CKD and How?
Which Hypoglycaemic Agents to use in Type 2 Diabetes and CKD and How?
DCCT, UKPDS and Kumamoto studies clearly indicatethat good glycaemic control can reduce the risk of nephropathyin subjects with both type 1 and type 2 diabetes. Furthermore, the recent ADVANCE trial confirmed that much tighter glycaemiccontrol (mean HbA1c = 6.5%) is beneficial for nephropathy insubjects with type 2 diabetes. In order to achieve tightglycaemic control, we would like to try to describe which hypoglycaemicagents to use in type 2 diabetic subjects with CKD and how, in this comment.
Abstract
DCCT, UKPDS and Kumamoto studies clearly indicatethat good glycaemic control can reduce the risk of nephropathyin subjects with both type 1 and type 2 diabetes. Furthermore, the recent ADVANCE trial confirmed that much tighter glycaemiccontrol (mean HbA1c = 6.5%) is beneficial for nephropathy insubjects with type 2 diabetes. In order to achieve tightglycaemic control, we would like to try to describe which hypoglycaemicagents to use in type 2 diabetic subjects with CKD and how, in this comment.
Source...